Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07620444

Spectral Precise Image-Colon Cancer

This is a single-center, comparative, observational study. Datasets will be collected from patients with pathologically confirmed colon cancer who undergo abdomen-pelvis enhanced spectral CT scan.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

This is a single-center, comparative, observational study. Datasets will be collected from patients with pathologically confirmed colon cancer who undergo abdomen-pelvis enhanced spectral CT scan at investigational center, including retrospective and prospective data. Based on the Dose Right Index (DRI) derived from CT image data, relevant data will be collected at a 1:1 ratio for the conventional radiation dose group (RD group, DRI = 21) and the low radiation dose group (LD group, DRI = 18). A total of 100 cases of datasets is expected to be collected. All CT raw data will be transmitted to Philips after the completion of the de-identification process. For the three-phase data of the LD group (plain scan, arterial phase and venous phase), offline reconstruction will be performed using the Spectral Precise Image algorithm to generate conventional images and VMI-40 keV images. A total of six image sequences will be quantitatively and qualitatively evaluated and compared. For both groups, conventional images and VMI-40 keV images will be reconstructed using iDose4.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients pathologically confirmed with colon cancer via endoscopic biopsy.
  • Patients who underwent preoperative abdominopelvic enhanced spectral CT.
  • Study participant with age ≥ 18 years old.
  • Study participants that have signed Informed Consent Form (ICF).

Exclusion criteria

  • The clinical data or pathological information is considered incomplete after evaluation by the investigator.
  • The investigator determined that poor image quality (e.g. obvious artifacts, missing critical scan layers) would not satisfy post-processing analysis.
  • Data of patients deemed inappropriate for inclusion after evaluation by the investigator.

Treatment and study plan

This is an observational study

Device

This is an observational study

Primary outcomes

  1. subjective overall Image quality using 5-point Likert scale(1-5)

    Time frame: From the date of image reconstruction completion to the date of image evaluation completion, anticipated 3 Months.

    Radiologist will evaluate the overall image quality using 5 Likert scale ranging from 1(poor) to 5 (Excellent)

  2. Objective image quality

    Time frame: From the date reconstruction completion to the date of image evaluation completion, anticipated 3months.

    The objective image quality is evaluated by measuring the CT value shown in the image.

Study contacts

Contact information is provided by the study sponsor or research team.

Miao Chuan Xie

CONTACT

[email protected]

+8618903050011

Sponsors and collaborators

Lead sponsor

Philips Clinical & Medical Affairs Global

Industry

Collaborators

  • Sun Yat-Sen University Cancer Center

Registry information

Official study title

CT Image Quality Assessment of Colon Cancer Using Spectral Precise Image Deep Learning Reconstruction

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jun 2, 2026
Registry last updated
Jun 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.